ArticleJournal of clinical microbiology2010
Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling.
Article in Journal of clinical microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 72 citations in OpenAlex.
- Evaluation of Apolipoprotein-A1 genetic polymorphisms as biomarkers for Chagas cardiomyopathy in patients from Córdoba, Argentina.Molecular biology reports · 2025Observational
- Preliminary screening of urinary host protein biomarkers for Schistosomiasis haematobium: A proteome profiling study identifying candidate diagnostic targets in school-aged children.PLoS neglected tropical diseases · 2025Article
- The Hidden Hand of Asymptomatic Infection Hinders Control of Neglected Tropical Diseases: A Modeling Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Persistent Biofluid Small-Molecule Alterations Induced byACS infectious diseases · 2023Article
- Intra-hostMicrobiology spectrum · 2023Article
- Persistent biofluid small molecule alterations induced bybioRxiv : the preprint server for biology · 2023Article
- Role of the Complement System in the Modulation of T-Cell Responses in Chronic Chagas Disease.Frontiers in cellular and infection microbiology · 2022Review
- Fibronectin degradation as biomarker forParasitology · 2021Article
- Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy.PloS one · 2021Article
- A novel Trypanosoma cruzi secreted antigen as a potential biomarker of Chagas disease.Scientific reports · 2020Article
- A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection.Antimicrobial agents and chemotherapy · 2019Article
- Identification of newly developed advanced schistosomiasis with MALDI-TOF mass spectrometry and ClinProTools analysis.Parasite (Paris, France) · 2019Article
- Validation of Apolipoprotein A-1 and Fibronectin Fragments as Markers of Parasitological Cure for Congenital Chagas Disease in Children Treated With Benznidazole.Open forum infectious diseases · 2018Article
- Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging.PloS one · 2018Article
- Serum Carbonic Anhydrase 1 is a Biomarker for Diagnosis of HumanThe American journal of tropical medicine and hygiene · 2017Article
- New detection method in experimental mice for schistosomiasis: ClinProTool and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.Parasitology research · 2016Article
- Discovery and characterization of potential prognostic biomarkers for dengue hemorrhagic fever.The American journal of tropical medicine and hygiene · 2014Article
- Recent advances in clinical parasitology diagnostics.Current infectious disease reports · 2014Article
- Biomarkers in Trypanosoma cruzi-infected and uninfected individuals with varying severity of cardiomyopathy in Santa Cruz, Bolivia.PLoS neglected tropical diseases · 2014Article
- Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment.BMC infectious diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 4 countries.
Funding
Abstract
More than 10 million people are thought to be infected with Trypanosoma cruzi, primarily in the Americas. The clinical manifestations of Chagas' disease (CD) are variable, but most subjects remain asymptomatic for decades. Only 15 to 30% eventually develop terminal complications. All current diagnostic tests have limitations. New approaches are needed for blood bank screening as well as for improved diagnosis and prognosis. Sera from subjects with asymptomatic CD (n = 131) were compared to those from uninfected controls (n = 164) and subjects with other parasitic diseases (n = 140), using protein array mass spectrometry. To identify biomarkers associated with CD, sera were fractionated by anion-exchange chromatography and bound to two commercial ProteinChip array chemistries: WCX2 and IMAC3. Multiple candidate biomarkers were found in CD sera (3 to 75.4 kDa). Algorithms employing 3 to 5 of these biomarkers achieved up to 100% sensitivity and 98% specificity for CD. The biomarkers most useful for diagnosis were identified and validated. These included MIP1 alpha, C3a anaphylatoxin, and unusually truncated forms of fibronectin, apolipoprotein A1 (ApoA1), and C3. An antipeptide antiserum against the 28.9-kDa C terminus of the fibronectin fragment achieved good specificity (90%) for CD in a Western blot format. We identified full-length ApoA1 (28.1 kDa), the major structural and functional protein component of high-density lipoprotein (HDL), as an important negative biomarker for CD, and relatively little full-length ApoA1 was detected in CD sera. This work provides proof of principle that both platform-dependent (i.e., mass spectrometry-based) and platform-independent (i.e., Western blot) tests can be generated using high-throughput mass profiling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.